Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Synthetic active peptide fragments

a technology of synthetic active peptides and peptide fragments, which is applied in the field of synthetic active peptide fragments, can solve the problems of large influence gap, inability to use vaccines in prevention and control programmes, and inability to achieve the effect of preventing and controlling disease,

Inactive Publication Date: 2007-01-04
FUNDACAO OSWALDO CRUZ FIOCRUZ
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0041] It is another object of the present invention to provide a process for constructing active peptides which mimic the Sm14 antigen or related FABPs or prevent the interaction between helminth pathogens and receptors.
[0042] It is yet another object of the present invention to provide an immunogenic compositions able to confer at least partial protection against infection with pathogenic helminths, and thus serve as vaccines against same.

Problems solved by technology

Concerning pathogenic helminths which are parasitic worms and cause human and veterinary diseases, such as schistosomiasis and fasciolosis, at the moment, no vaccines are currently used in prevention and control programmes.
There is still a great gap in the knowledge of the variables influencing the dynamics of transmission of these diseases in connection with vaccines and vaccination protocol design.
Nowadays, the use of vaccines composed of pathogen components or attenuated parasites for human immunization is considered impractical and potentially dangerous.
The worry in using such complex and undefined mixtures comes from the fact that the majority of components stimulate non-functional immune responses and some components can even be detrimental to vaccinated subjects, when toxic products of lipid peroxidation can be generated by immune attack against other parasite antigens, particularly surface antigens.
However, vaccines which are based on the use of proteins belonging to the pathogen, be they altered or not, are not always easily obtainable.
Difficulties in the extraction, purification, quantitative analysis and modification of such proteins are common problems with this type of vaccine.
Solutions exist for some such cases but these may result in an additional onus to the protein production process which goes against the general principle that a vaccine should be of relatively low cost and should be globally accessible.
However, while some success has been achieved, these molecules are quite large.
However, it can be difficult to predict which peptide fragments will be immunogenic and lead to the development of a neutralizing response.
This presents a series of problems.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthetic active peptide fragments
  • Synthetic active peptide fragments
  • Synthetic active peptide fragments

Examples

Experimental program
Comparison scheme
Effect test

example 1

Method for Obtaining the Peptide

[0091] The three-dimensional structure of Sm14, as built by comparative homology modeling and described in Tendler et al. (1996), was used as the basis for obtaining peptide fragments for synthesis and subsequent vaccination trials. It should be noted that in previous studies we described likely discontinuous epitopes responsible for the immune cross-reactivity between Sm14 and Fh15 and a summary of these results has been given above.

[0092] The residues predicted to participate in such epitopes were identified on the basis of the fact that they are identical in the two parasite molecules and yet only poorly conserved in human homologues. Due to the fact that few of the predicted epitopic residues were present in continuous stretches of the amino acid sequence, a design strategy was elaborated in order to incorporate more than one continuous segment into a single unified peptide.

[0093] In order to aid in obtaining segments of the polypeptide chain w...

example 2

Peptide Synthesis

[0109] The peptides according to the present invention were synthesized by usual procedures (from the state of the art) and provided in the form of C-terminal amides as free peptides, at a purity of greater than 97%.

example 3

Expression of Recombinant Sm14 (r-Sm14)

[0110] In order to provide control experiments the recombinant Sm14 protein expressed by the pRSETA-6×His-Sm14 construct was obtained after transformation of chemically competent E. coli BL21(DE3) as described in Ramos C. R. R et al., Mem Inst. Oswaldo Cruz, R10 de Janeiro, Vol. 96, Suppl.: 131-135, 2001, herein incorporated by reference.

Materials and Methods

[0111] The pRSET A, B, C expression system was purchased from Invitrogen. The pET3-His (Chem & Tsonwin 1994) was obtained from the National Institute of Genetic, Japan. All the reagents used here were of analytical grade.

Expression and Purification of Recombinant Sm14

[0112] The recombinant Sm14 derived from pGEMEX expression system (Promega) was purified as described (“A Schistosoma mansoni fatty acid binding protein, Sm14, is the potential basis of a dual-purpose anti-helminth vaccine”. Proc. Natl. Acad. Sci. 93: 269-273 and U.S. Pat. No. 5,730,984).

[0113] The recombinant Sm14 prot...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Atomic weightaaaaaaaaaa
Conformational barrieraaaaaaaaaa
Compositionaaaaaaaaaa
Login to View More

Abstract

The present invention relates to peptide fragments which have one or more shared and / or similar amino acid sequences to amino acid sequences of specific portions of the 14 kDa protein of S. mansoni (Sm14) or related FABPs (Fatty Acid Binding Proteins), the said peptide fragments functioning as continuous or discontinuous epitopic regions of the molecule or mimicking its biological activity. More particularly, the present invention relates to a method for constructing active peptide fragments, peptide fragments, immunogenic composition and diagnostic kit using said peptide fragments.

Description

[0001] The present application is a divisional of U.S. application Ser. No. 10 / 113,946, filed Apr. 2, 2002, the entire contents of which is hereby incorporated by reference.FIELD OF THE INVENTION [0002] The present invention relates to peptide fragments which have one or more shared and / or similar amino acid sequences to amino acid sequences of specific portions of the 14 kDa protein of S. mansoni (Sm14) or related FABPs (Fatty Acid Binding Proteins), the said peptide fragments functioning as continuous or discontinuous epitopic regions of the molecule or mimicking its biological activity. More particularly, the present invention relates to a method for constructing active peptide fragments, peptide fragments, immunogenic composition and diagnostic test kit using said fragments. BACKGROUND OF THE INVENTION [0003] Sm14, belonging to the family of Fatty Acid Binding Proteins (FABPs), is a cross reactive antigen showing a high level of protection against schistosomiasis and fasciolosis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G06F19/00C07K1/02A61K39/00C07K14/435
CPCA61K39/00C07K14/4354C07K2319/00C07K14/43559G01N33/6893Y02A50/30A61K39/0003
Inventor TENDLER, MIRIAMGARRAT, RICHARD CHARLESKATZ, NAFTALESIMPSON, ANDREW JOHN GEORGEDE BARRIENTOS, FRANK JEFFERSON ALARCONVILAR, MONICA MAGNOALMEIDA, MARILIA SIRIANNI DOS SANTO
Owner FUNDACAO OSWALDO CRUZ FIOCRUZ
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com